Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Shares Outstanding (Weighted Average) (2024 - 2025)

Xilio Therapeutics' Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $105.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 65.98% year-over-year to $105.3 million; the TTM value through Sep 2025 reached $105.3 million, up 65.98%, while the annual FY2024 figure was $53.5 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $105.3 million at Xilio Therapeutics, up from $85.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $105.3 million in Q3 2025 and bottomed at $27.9 million in Q1 2024.